BioXcel Therapeutics, Inc. (BTAI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 900K 1.8M 2.7M Q2 '23: 1M Q3 '23: 1.2M Q4 '23: 1.4M Q1 '24: 1.8M Q2 '24: 2.4M Q3 '24: 2.3M Q4 '24: 2.3M Q1 '25: 1.9M Q2 '25: 868K Q3 '25: 752K Q4 '25: 642K Q1 '26: 680K Q2 '26: 742K Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit TTM

-1.5M -1M -500K 0 500K 1M 1.5M Q2 '23: 983K Q3 '23: 686K Q4 '23: 119K Q1 '24: 424K Q2 '24: 1M Q3 '24: 250K Q4 '24: 122K Q1 '25: -226K Q2 '25: -1.3M Q3 '25: -212K Q4 '25: 478K Q1 '26: 247K Q2 '26: 394K Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-210M -140M -70M 0 70M 140M 210M Q3 '21: -101.9M Q4 '21: -106.9M Q1 '22: -112M Q2 '22: -120.7M Q3 '22: -132.9M Q4 '22: -159.7M Q1 '23: -179.4M Q2 '23: -195.5M Q3 '23: -204.8M Q4 '23: -171.8M Q1 '24: -144.7M Q2 '24: -109.6M Q3 '24: -76.6M Q4 '24: -67.2M Q1 '25: -53.2M Q2 '25: -51.7M Q3 '25: -50.7M Q4 '25: -50.5M Q1 '26: -50.6M Q2 '26: -44.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-240M -160M -80M 0 80M 160M 240M Q3 '21: -101.9M Q4 '21: -106.9M Q1 '22: -112M Q2 '22: -122.1M Q3 '22: -137.1M Q4 '22: -165.8M Q1 '23: -187.1M Q2 '23: -202.9M Q3 '23: -211.6M Q4 '23: -179.1M Q1 '24: -153M Q2 '24: -107.8M Q3 '24: -71M Q4 '24: -59.6M Q1 '25: -40.1M Q2 '25: -51M Q3 '25: -68.2M Q4 '25: -69.9M Q1 '26: -75.3M Q2 '26: -70.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 800K 1.6M 2.4M Q2 '23: 55K Q3 '23: 556K Q4 '23: 1.3M Q1 '24: 1.3M Q2 '24: 1.4M Q3 '24: 2M Q4 '24: 2.1M Q1 '25: 2.1M Q2 '25: 2.1M Q3 '25: 964K Q4 '25: 164K Q1 '26: 433K Q2 '26: 348K Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -82.5M Q4 '21: -82.2M Q1 '22: -94.9M Q2 '22: -105.6M Q3 '22: -116.6M Q4 '22: -135.3M Q1 '23: -155.3M Q2 '23: -160.4M Q3 '23: -166.8M Q4 '23: -155M Q1 '24: -120.4M Q2 '24: -105.3M Q3 '24: -84.1M Q4 '24: -72M Q1 '25: -66.4M Q2 '25: -55.8M Q3 '25: -58.2M Q4 '25: -57.6M Q1 '26: -57.4M Q2 '26: -50.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q2 '19: -20.3M Q3 '19: -24.5M Q4 '19: -28M Q1 '20: -33.9M Q2 '20: -42.5M Q3 '20: -54M Q4 '20: -66.7M Q1 '21: -74.4M Q2 '21: -82.1M Q3 '21: -83.2M Q4 '21: -82.6M Q1 '22: -95.2M Q2 '22: -105.8M Q3 '22: -116.8M Q4 '22: -135.5M Q2 '25: -55.8M Q3 '25: -58.2M Q4 '25: -57.6M Q1 '26: -57.4M Q2 '26: -50.9M Q3 '19 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '21: 24.5M Q2 '21: 25M Q3 '21: 28M Q1 '22: 28K Q2 '22: 28M Q3 '22: 28M Q1 '23: 28.6M Q2 '23: 29.2M Q3 '23: 29.3M Q1 '24: 1.9M Q2 '24: 2.5M Q3 '24: 2.6M Q1 '25: 4.8M Q2 '25: 7.8M Q3 '25: 14.2M Q1 '26: 23.6M Q2 '26: 30.3M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-120.00 -80.00 -40.00 0.00 40.00 80.00 120.00 Q3 '20: -3.37 Q4 '20: -3.77 Q1 '21: -4.06 Q2 '21: -4.11 Q3 '21: -4.00 Q4 '21: -4.07 Q1 '23: -6.64 Q2 '23: -7.12 Q3 '23: -7.35 Q4 '23: -98.32 Q1 '24: -110.37 Q2 '24: -111.84 Q3 '24: -115.27 Q4 '24: -25.25 Q1 '25: -12.86 Q2 '25: -12.01 Q3 '25: -9.04 Q4 '25: -5.73 Q1 '26: -4.77 Q2 '26: -2.81 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.